Literature DB >> 24809487

Does preoperative neutrophil lymphocyte ratio predict risk of recurrence and occult central nodal metastasis in papillary thyroid carcinoma?

Brian Hung-Hin Lang1, Cathy Po-Ching Ng, Kin Bun Au, Kai Pun Wong, Kandy K C Wong, Koon Yat Wan.   

Abstract

BACKGROUND: Preoperative neutrophil to lymphocyte ratio (NLR) might be prognostic in papillary thyroid carcinoma (PTC). Given the controversy of prophylactic central neck dissection (pCND) in clinically nodal-negative (cN0) PTC, our study evaluated whether preoperative NLR predicted disease-free survival (DFS) and occult central nodal metastasis (CNM) in cN0 PTC.
METHODS: A total of 191 patients who underwent pCND were analyzed. Complete blood counts with differential counts were taken before operation. NLR was calculated by dividing preoperative neutrophil count with lymphocyte count. Patients were categorized into NLR tertiles: first (NLR < 1.93; n = 63), second (NLR = 1.93-2.79; n = 64), and third tertile (NLR > 2.79; n = 64). Four other patient types, namely, benign nodular goiter, clinically nodal-positive (cN1) PTC, poorly differentiated thyroid carcinoma, and anaplastic thyroid carcinoma (ATC), were used as references.
RESULTS: Age at operation (p < 0.001) and tumor size (p = 0.037) significantly increased with higher NLR. First tertile had significantly more TNM stage I tumors (p = 0.01) and lowest MACIS score (p = 0.002). Tumor size [hazard ratio (HR) 1.422, 95% confidence interval (CI) 1.119-1.809, p = 0.004] and multicentricity (HR = 2.545, 95% CI 1.073-6.024, p = 0.034) independently predicted DFS, whereas old age [odds ratio (OR) 1.026, 95% CI 1.006-1.046, p = 0.009), male (OR 2.882, 95% CI 1.348-6.172, p = 0.006), and large tumor (OR 1.567, 95% CI 1.209-2.032, p = 0.001) independently predicted occult CNM. NLR was not significantly associated with DFS or occult CNM. ATC had significantly higher NLR than cN1 PTC (7.28 vs. 2.74, p < 0.001).
CONCLUSIONS: Although a higher NLR may imply a poorer tumor profile, it was not significantly associated with a worse DFS or higher risk of occult CNM in cN0 PTC. Perhaps, future research should focus on the prognostic value in other thyroid cancer types with a poorer prognosis.

Entities:  

Mesh:

Year:  2014        PMID: 24809487     DOI: 10.1007/s00268-014-2630-z

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  27 in total

1.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

2.  Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients.

Authors:  Ling Zhang; Wen-Jun Wei; Qing-Hai Ji; Yong-Xue Zhu; Zhuo-Ying Wang; Yu Wang; Cai-Ping Huang; Qiang Shen; Duan-Shu Li; Yi Wu
Journal:  J Clin Endocrinol Metab       Date:  2012-02-08       Impact factor: 5.958

Review 3.  Tumor-associated neutrophils: friend or foe?

Authors:  Zvi G Fridlender; Steven M Albelda
Journal:  Carcinogenesis       Date:  2012-03-16       Impact factor: 4.944

4.  The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.

Authors:  Lorien Paulson; Maisie Shindo; Kathryn Schuff; Christopher Corless
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2012-01

5.  Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma.

Authors:  Qunzi Zhao; Jie Ming; Chunping Liu; Lan Shi; Xia Xu; Xiu Nie; Tao Huang
Journal:  Ann Surg Oncol       Date:  2012-09-13       Impact factor: 5.344

6.  Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer.

Authors:  Chien-Liang Liu; Jie-Jen Lee; Tsang-Pai Liu; Yuan-Ching Chang; Yi-Chiung Hsu; Shih-Ping Cheng
Journal:  J Surg Oncol       Date:  2012-09-20       Impact factor: 3.454

7.  Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability.

Authors:  Brian Lang; Chung-Yau Lo; Wai-Fan Chan; King-Yin Lam; Koon-Yat Wan
Journal:  Ann Surg Oncol       Date:  2007-02-21       Impact factor: 5.344

8.  The neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis.

Authors:  Shouyu Wang; Zhen Zhang; Fengqi Fang; Xue Gao; Wei Sun; Huanran Liu
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

9.  Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features.

Authors:  Kyung-Eun Kim; Eun-Kyung Kim; Jung Hyun Yoon; Kyung Hwa Han; Hee Jung Moon; Jin Young Kwak
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

10.  Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers.

Authors:  Brian Hung-Hin Lang; Sin-Ming Chow; Chung-Yau Lo; Stephen C K Law; King-Yin Lam
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

View more
  27 in total

1.  Neutrophil-lymphocyte ratio as a predictor of recurrence and progression in patients with high-grade pT1 bladder cancer.

Authors:  Mehmet Emin Ozyalvacli; Gulzade Ozyalvacli; Ramazan Kocaaslan; Kursat Cecen; Ugur Uyeturk; Eray Kemahlı; Adnan Gucuk
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

2.  Accurate use of neutrophil to lymphocyte ratio in predicting prognosis of papillary thyroid carcinoma.

Authors:  Erdim Sertoglu; Huseyin Kayadibi; Metin Uyanik
Journal:  World J Surg       Date:  2014-12       Impact factor: 3.352

3.  Accurate use of neutrophil to lymphocyte ratio in predicting prognosis of papillary thyroid carcinoma: reply.

Authors:  Brian Hung-Hin Lang
Journal:  World J Surg       Date:  2014-12       Impact factor: 3.352

Review 4.  The immune network in thyroid cancer.

Authors:  Maria Rosaria Galdiero; Gilda Varricchi; Gianni Marone
Journal:  Oncoimmunology       Date:  2016-03-30       Impact factor: 8.110

5.  Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Differentiated Thyroid Carcinoma Having Distant Metastasis: A Comparison With Thyroglobulin-doubling Rate and Tumor Volume-doubling Rate.

Authors:  Yasuhiro Ito; Naoyoshi Onoda; Minoru Kihara; Akihiro Miya; Akira Miyauchi
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

6.  The systemic immune-inflammation index-based model is an effective biomarker on predicting central lymph node metastasis in clinically nodal-negative papillary thyroid carcinoma.

Authors:  Zeyu Zhang; Fada Xia; Wenlong Wang; Yun Huang; Xinying Li
Journal:  Gland Surg       Date:  2021-04

7.  The diagnostic predictive value of neutrophil-to-lymphocyte ratio in thyroid cancer adjusted for tumor size.

Authors:  Taek Yoon Cheong; Sang Duk Hong; Keun-Woo Jung; Yoon Kyoung So
Journal:  PLoS One       Date:  2021-05-11       Impact factor: 3.240

Review 8.  Immune Landscape of Thyroid Cancers: New Insights.

Authors:  Elisa Menicali; Martina Guzzetti; Silvia Morelli; Sonia Moretti; Efisio Puxeddu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-27       Impact factor: 5.555

Review 9.  Pre-treatment neutrophil-to-lymphocyte ratio is an independent prognostic factor in head and neck squamous cell carcinoma: Meta-analysis and trial sequential analysis.

Authors:  Pierluigi Mariani; Diana Russo; Marco Maisto; Giuseppe Troiano; Vito Carlo Alberto Caponio; Marco Annunziata; Luigi Laino
Journal:  J Oral Pathol Med       Date:  2021-12-09       Impact factor: 3.539

10.  Association of the Preoperative Inflammation-Based Scores with TNM Stage and Recurrence in Patients with Papillary Thyroid Carcinoma: A Retrospective, Multicenter Analysis.

Authors:  Wenjie Chen; Tao Wei; Zhihui Li; Rixiang Gong; Jianyong Lei; Jingqiang Zhu; Tao Huang
Journal:  Cancer Manag Res       Date:  2020-03-11       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.